II 

118TH CONGRESS 

2D SESSION S. 4774 

To provide for the periodic issuance of up-to-date clinical guidance on addressing the health effects of per- and polyfluoroalkyl substances (PFAS), 

and for other purposes. 

IN THE SENATE OF THE UNITED STATES 

JULY 25, 2024 

Mrs. SHAHEEN (for herself and Ms. COLLINS) introduced the following bill; 

which was read twice and referred to the Committee on Health, Education, Labor, and Pensions 

A BILL 

To provide for the periodic issuance of up-to-date clinical 

guidance on addressing the health effects of per- and 

polyfluoroalkyl substances (PFAS), and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Better Care for PFAS 

5 Patients Act of 2024’’. 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
2 

•S 4774 IS

1 SEC. 2. PFAS HEALTH EFFECTS ASSESSMENT, REC2 OMMENDATIONS, AND GUIDANCE. 

3 (a) PERIODIC ASSESSMENT AND RECOMMENDA4 TIONS.— 

5 (1) AGREEMENT.—The Director of the Agency 

6 for Toxic Substances and Disease Registry (in this 

7 section referred to as the ‘‘Director’’) shall enter 

8 into an agreement with the National Academies of 

9 Sciences, Engineering, and Medicine (or another ap10 propriate entity if the National Academies declines 

11 to enter into such agreement) under which the Na12 tional Academies or the other appropriate entity 

13 agrees— 

14 (A) to assess the health effects of per- and 

15 polyfluoroalkyl substances (in this section re16 ferred to as ‘‘PFAS’’) that can be measured in 

17 human tissues; 

18 (B) to formulate clinical recommendations 

19 on addressing such health effects; 

20 (C) not later than 2 years after the date 

21 of entry into such agreement, to complete the 

22 initial assessment under subparagraph (A) and 

23 formulate the initial recommendations under 

24 subparagraph (B); and 

25 (D) to update the most recent assessment 

26 and recommendations under this paragraph— 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
3 

•S 4774 IS

1 (i) every 5 years; or 

2 (ii) more frequently as determined 

3 necessary by the Director based on an as4 sessment of the science. 

5 (2) CONSULTATION.—In carrying out the as6 sessments under paragraph (1), the National Acad7 emies of Sciences, Engineering, and Medicine or 

8 other appropriate entity shall engage with PFAS ex9 posed communities and solicit input from members 

10 of such communities regarding their experiences 

11 with PFAS exposure, testing, and clinical follow-up. 

12 (3) TIMING OF ENTRY INTO AGREEMENT.—The 

13 Director shall enter into the agreement required by 

14 paragraph (1) not later than 60 days after the date 

15 of enactment of this Act. 

16 (b) UP-TO-DATE GUIDANCE.—Based on the results 

17 of the most recent assessment and recommendations 

18 under subsection (a), the Director, in consultation with 

19 the entity with which the Director enters into the agree20 ment under subsection (a), shall— 

21 (1) not later than 5 years after the date of 

22 entry into the agreement required by subsection 

23 (a)— 

24 (A) issue up-to-date clinical guidance on 

25 addressing the health effects of PFAS; 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
4 

•S 4774 IS

1 (B) post such guidance on the public 

2 website of the Agency for Toxic Substances and 

3 Disease Registry; and 

4 (C) disseminate such guidance to State 

5 and local public health authorities and appro6 priate health care professionals; and 

7 (2) every 5 years thereafter, or more frequently 

8 as determined necessary by the Director based on an 

9 assessment of the science, issue, post, and dissemi10 nate up-to-date guidance as described in paragraph 

11 (1). 

Æ 


kjohnson on DSK7ZCZBW3PROD with $$_JOB